These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 19545216

  • 1. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
    Gschwend MH, Aagren M, Valentine WJ.
    J Med Econ; 2009 Jun; 12(2):114-23. PubMed ID: 19545216
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden.
    Valentine WJ, Aagren M, Haglund M, Ericsson A, Gschwend MH.
    Scand J Public Health; 2011 Feb; 39(1):79-87. PubMed ID: 20688795
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 4. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
    Smith-Palmer J, Fajardo-Montañana C, Pollock RF, Ericsson A, Valentine WJ.
    J Med Econ; 2012 Aug; 15(5):977-86. PubMed ID: 22563742
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
    Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU.
    Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
    [Abstract] [Full Text] [Related]

  • 6. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P.
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [Abstract] [Full Text] [Related]

  • 7. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
    Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M.
    Diabet Med; 2012 Mar; 29(3):303-12. PubMed ID: 21951030
    [Abstract] [Full Text] [Related]

  • 8. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [Abstract] [Full Text] [Related]

  • 9. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL, Willis WD, Foos V.
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [Abstract] [Full Text] [Related]

  • 10. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 11. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V, Heise T, Dellweg S, Elbroend B, Minns I, Home PD.
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [Abstract] [Full Text] [Related]

  • 12. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
    Pfohl M, Schädlich PK, Dippel FW, Koltermann KC.
    J Med Econ; 2012 Oct; 15 Suppl 2():14-27. PubMed ID: 22812690
    [Abstract] [Full Text] [Related]

  • 13. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
    Ridderstråle M, Jensen MM, Gjesing RP, Niskanen L.
    J Med Econ; 2013 Jan; 16(4):468-78. PubMed ID: 23384160
    [Abstract] [Full Text] [Related]

  • 15. [Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark].
    Palmer AJ, Lammert M, Hermansen K.
    Ugeskr Laeger; 2008 Apr 07; 170(15):1250-4. PubMed ID: 18433583
    [Abstract] [Full Text] [Related]

  • 16. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O, Breitscheidel L, Benter U, Dippel FW, Müller M, Volk M, Pfohl M.
    J Med Econ; 2008 Apr 07; 11(4):695-712. PubMed ID: 19450076
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.
    Curr Med Res Opin; 2009 May 07; 25(5):1273-84. PubMed ID: 19366302
    [Abstract] [Full Text] [Related]

  • 18. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008 May 07; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

  • 19. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
    Roze S, Valentine WJ, Evers T, Palmer AJ.
    Curr Med Res Opin; 2006 Jul 07; 22(7):1415-24. PubMed ID: 16834840
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ.
    Value Health; 2009 Jul 07; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.